secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001193125-24-075932
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics appoints John Cox as President and CEO, succeeding Joshua Brumm
--------------------------------------------------------------------------------

- John Cox appointed President and CEO effective March 25, 2024; also elected Class I director.
- Joshua Brumm resigns as CEO and from the Board; will serve as consultant for 12 months.
- Cox receives $700K base salary, up to 60% annual bonus, and option for 679,853 shares.
- Brumm gets separation: 12 months salary, COBRA, and partial equity acceleration.
- Board adopts 2024 Inducement Equity Plan authorizing 900,000 shares for new hires.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/d93072d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-075932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer